Australia markets closed

Cellectar Biosciences Inc (NV4.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
2.8400-0.0400 (-1.40%)
As of 02:10PM CEST. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-37,983
-37,983
-28,601
-24,122
-15,094
Depreciation & amortisation
192.375
192.375
148.435
149.915
141.453
Stock-based compensation
2,410
2,410
1,453
1,124
467.541
Change in working capital
3,476
3,476
1,684
198.761
671.239
Other working capital
-33,241
-33,241
-25,448
-22,710
-13,995
Other non-cash items
58.051
58.051
90.432
77.721
66.476
Net cash provided by operating activities
-32,377
-32,377
-25,222
-22,569
-13,933
Cash flows from investing activities
Investments in property, plant and equipment
-864.038
-864.038
-225.971
-141.361
-62.353
Net cash used for investing activities
-864.038
-864.038
-225.971
-141.361
-62.353
Cash flows from financing activities
Debt repayment
-
-
-
-
0
Common stock issued
-
-
9,611
34.873
59,719
Net cash used provided by (used for) financing activities
22,940
22,940
9,611
1,249
60,546
Net change in cash
-10,301
-10,301
-15,838
-21,461
46,551
Cash at beginning of period
19,866
19,866
35,704
57,165
10,615
Cash at end of period
9,565
9,565
19,866
35,704
57,165
Free cash flow
Operating cash flow
-32,377
-32,377
-25,222
-22,569
-13,933
Capital expenditure
-864.038
-864.038
-225.971
-141.361
-62.353
Free cash flow
-33,241
-33,241
-25,448
-22,710
-13,995